On April 12, 2024, Bloomberg featured Wolf Popper’s successful appeal at the Fourth Circuit Court of Appels of the dismissal of a class action against Labcorp related to its use of the deceptive and misleading Patient Acknowledgment of Estimated Financial Responsibility form (“Patient Acknowledgment”). As the Bloomberg article notes, the Fourth Circuit held that under Nevada law, Labcorp’s failure to disclose its list prices—the prices that would be charged to patients whose insurance does not cover one or more tests—is a violation of the Nevada Deceptive Trade Practices Act.
The case is proceeding to discovery and an eventual class certification motion.